ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.

The art of building a biologic drug

The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Join us for a Life Science seminar on april 9th on GoCo

Festo products and solutions are setting the stage for better health through innovative solutions for reliable medical technology and precise, reproducible labo...

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

How to avoid measurement inaccuracies due to wear

Expert tip from ZEISS.

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

Från apotekare till poddare – Magnus Lejelöv har rösten som verktyg

Magnus Lejelöv har över 20 års erfarenhet från läkemedelssektorn och har intervjuat nära två hundra vårdprofiler i sina poddar. I maj står han på scenen i Lund ...

Cecilia Wadell ska ta Alzecures kliniska utveckling vidare

Alzecure har utsett Cecilia Wadell till ny utvecklingschef.

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg 2026

Automated dispensing of a viscous hydrogel

A suitable solution developed for UPM Biomedicals In the Festo LifeTech Application Center we tested a setup for UPM Biomedicals for the automatic dispensing of...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).